XML 122 R98.htm IDEA: XBRL DOCUMENT
v3.22.4

Segments of Business and Geographic Areas - Sales by Segment of Business (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Jan. 01, 2023 | Jan. 02, 2022 | Jan. 03, 2021
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 94,943 | $ 93,775 | $ 82,584
Percentage Change In Sales By Segment Of Business | 1.30% | 13.60% |
Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 14,953 | $ 15,035 | 14,450
Percentage Change In Sales By Segment Of Business | (0.50%) | 4.00% |
Pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 52,563 | $ 51,680 | 45,175
Percentage Change In Sales By Segment Of Business | 1.70% | 14.40% |
Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 16,935 | $ 16,750 | 15,055
Percentage Change In Sales By Segment Of Business | 1.10% | 11.30% |
Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 5,449 | $ 5,825 | 3,543
Percentage Change In Sales By Segment Of Business | (6.50%) | 64.40% |
Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 6,893 | $ 6,988 | 6,526
Percentage Change In Sales By Segment Of Business | (1.40%) | 7.10% |
Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 15,983 | $ 14,548 | 12,367
Percentage Change In Sales By Segment Of Business | 9.90% | 17.60% |
Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,417 | $ 3,450 | 3,148
Percentage Change In Sales By Segment Of Business | (1.00%) | 9.60% |
Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,887 | $ 4,119 | 4,534
Percentage Change In Sales By Segment Of Business | (5.60%) | (9.20%) |
Medical Devices |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 27,427 | $ 27,060 | 22,959
Percentage Change In Sales By Segment Of Business | 1.40% | 17.90% |
Medical Devices | Interventional Solutions |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 4,300 | $ 3,971 | 3,046
Percentage Change In Sales By Segment Of Business | 8.30% | 30.40% |
Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 8,587 | $ 8,588 | 7,763
Percentage Change In Sales By Segment Of Business | 0.00% | 10.60% |
Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 9,690 | $ 9,812 | 8,232
Percentage Change In Sales By Segment Of Business | (1.20%) | 19.20% |
Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 4,849 | $ 4,688 | 3,919
Percentage Change In Sales By Segment Of Business | 3.40% | 19.60% |
OTC | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 6,031 | $ 5,627 | 5,221
Percentage Change In Sales By Segment Of Business | 7.20% | 7.80% |
Skin health/Beauty | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 4,352 | $ 4,541 | 4,450
Percentage Change In Sales By Segment Of Business | (4.20%) | 2.00% |
Oral Care | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,505 | $ 1,645 | 1,641
Percentage Change In Sales By Segment Of Business | (8.50%) | 0.20% |
Baby Care | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,461 | $ 1,566 | 1,517
Percentage Change In Sales By Segment Of Business | (6.70%) | 3.20% |
Women's Health | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 904 | $ 917 | 901
Percentage Change In Sales By Segment Of Business | (1.50%) | 1.80% |
Wound Care and Other | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 700 | $ 739 | 720
Percentage Change In Sales By Segment Of Business | (5.30%) | 2.60% |
Remicade | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,343 | $ 3,190 | 3,747
Percentage Change In Sales By Segment Of Business | (26.60%) | (14.90%) |
Simponi/Simponi Aria | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,184 | $ 2,276 | 2,243
Percentage Change In Sales By Segment Of Business | (4.00%) | 1.40% |
Stelara | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 9,723 | $ 9,134 | 7,707
Percentage Change In Sales By Segment Of Business | 6.50% | 18.50% |
Tremfya | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,668 | $ 2,127 | 1,347
Percentage Change In Sales By Segment Of Business | 25.40% | 57.90% |
Other Immunology | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 17 | $ 24 | 11
Percentage Change In Sales By Segment Of Business | (28.20%) |  |
COVID-19 | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,179 | 2,385 | 0
Percentage Change In Sales By Segment Of Business | (8.60%) |  |
EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,008 | $ 994 | 964
Percentage Change In Sales By Segment Of Business | 1.50% | 3.10% |
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,943 | $ 2,083 | 2,184
Percentage Change In Sales By Segment Of Business | (6.70%) | (4.60%) |
Other Infectious Diseases | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 318 | $ 363 | 396
Percentage Change In Sales By Segment Of Business | (12.30%) | (8.30%) |
CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 644 | $ 667 | 622
Percentage Change In Sales By Segment Of Business | (3.50%) | 7.30% |
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 4,140 | $ 4,022 | 3,653
Percentage Change In Sales By Segment Of Business | 3.00% | 10.10% |
RISPERDAL CONSTA | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 485 | $ 592 | 642
Percentage Change In Sales By Segment Of Business | (18.10%) | (7.70%) |
OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,623 | $ 1,706 | 1,610
Percentage Change In Sales By Segment Of Business | (4.90%) | 6.00% |
DARZALEX | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 7,977 | $ 6,023 | 4,190
Percentage Change In Sales By Segment Of Business | 32.40% | 43.80% |
ERLEADA | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,881 | $ 1,291 | 760
Percentage Change In Sales By Segment Of Business | 45.70% | 70.00% |
IMBRUVICA | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,784 | $ 4,369 | 4,128
Percentage Change In Sales By Segment Of Business | (13.40%) | 5.80% |
ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,770 | $ 2,297 | 2,470
Percentage Change In Sales By Segment Of Business | (22.90%) | (7.00%) |
Other Oncology | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 571 | $ 568 | 821
Percentage Change In Sales By Segment Of Business | 0.60% | (30.80%) |
OPSUMIT | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,783 | $ 1,819 | 1,639
Percentage Change In Sales By Segment Of Business | (2.00%) | 11.00% |
UPTRAVI | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,322 | $ 1,237 | 1,093
Percentage Change In Sales By Segment Of Business | 6.90% | 13.10% |
Other | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 313 | $ 395 | 416
Percentage Change In Sales By Segment Of Business | (20.80%) | (5.00%) |
Other | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 966 | $ 1,119 | 1,394
Percentage Change In Sales By Segment Of Business | (13.60%) | (19.70%) |
XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,473 | $ 2,438 | 2,345
Percentage Change In Sales By Segment Of Business | 1.40% | 4.00% |
INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 448 | $ 563 | 795
Percentage Change In Sales By Segment Of Business | (20.40%) | (29.30%) |
HIPS | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,514 | $ 1,480 | 1,280
Percentage Change In Sales By Segment Of Business | 2.30% | 15.60% |
KNEES | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,359 | $ 1,325 | 1,170
Percentage Change In Sales By Segment Of Business | 2.60% | 13.30% |
TRAUMA | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,871 | $ 2,885 | 2,614
Percentage Change In Sales By Segment Of Business | (0.50%) | 10.40% |
SPINE,SPORTS & OTHER | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,843 | $ 2,898 | 2,699
Percentage Change In Sales By Segment Of Business | (1.90%) | 7.40% |
ADVANCED | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 4,569 | $ 4,622 | 3,839
Percentage Change In Sales By Segment Of Business | (1.10%) | 20.40% |
GENERAL | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 5,121 | $ 5,190 | 4,392
Percentage Change In Sales By Segment Of Business | (1.30%) | 18.10% |
CONTACT LENSES/OTHER | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,543 | $ 3,440 | 2,994
Percentage Change In Sales By Segment Of Business | 3.00% | 14.90% |
SURGICAL | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,306 | $ 1,248 | 925
Percentage Change In Sales By Segment Of Business | 4.60% | 34.90% |
United States |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 48,580 | $ 47,156 | 43,133
Percentage Change In Sales By Segment Of Business | 3.00% | 9.30% |
United States | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 6,599 | $ 6,516 | 6,362
Percentage Change In Sales By Segment Of Business | 1.30% | 2.40% |
United States | Pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 28,604 | $ 27,954 | 25,735
Percentage Change In Sales By Segment Of Business | 2.30% | 8.60% |
United States | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 11,036 | $ 10,843 | 10,175
Percentage Change In Sales By Segment Of Business | 1.80% | 6.60% |
United States | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,680 | $ 2,249 | 1,735
Percentage Change In Sales By Segment Of Business | (25.30%) | 29.70% |
United States | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,570 | $ 3,347 | 3,091
Percentage Change In Sales By Segment Of Business | 6.70% | 8.30% |
United States | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 6,930 | $ 5,958 | 5,092
Percentage Change In Sales By Segment Of Business | 16.30% | 17.00% |
United States | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,346 | $ 2,365 | 2,133
Percentage Change In Sales By Segment Of Business | (0.80%) | 10.90% |
United States | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,042 | $ 3,192 | 3,509
Percentage Change In Sales By Segment Of Business | (4.70%) | (9.00%) |
United States | Medical Devices |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 13,377 | $ 12,686 | 11,036
Percentage Change In Sales By Segment Of Business | 5.40% | 14.90% |
United States | Medical Devices | Interventional Solutions |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,169 | $ 1,836 | 1,452
Percentage Change In Sales By Segment Of Business | 18.20% | 26.40% |
United States | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 5,321 | $ 5,126 | 4,779
Percentage Change In Sales By Segment Of Business | 3.80% | 7.30% |
United States | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,897 | $ 3,867 | 3,249
Percentage Change In Sales By Segment Of Business | 0.80% | 19.00% |
United States | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,990 | $ 1,857 | 1,557
Percentage Change In Sales By Segment Of Business | 7.20% | 19.30% |
United States | OTC | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,782 | $ 2,594 | 2,460
Percentage Change In Sales By Segment Of Business | 7.30% | 5.40% |
United States | Skin health/Beauty | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,337 | $ 2,400 | 2,350
Percentage Change In Sales By Segment Of Business | (2.60%) | 2.10% |
United States | Oral Care | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 635 | $ 637 | 683
Percentage Change In Sales By Segment Of Business | (0.30%) | (6.70%) |
United States | Baby Care | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 357 | $ 378 | 376
Percentage Change In Sales By Segment Of Business | (5.50%) | 0.50% |
United States | Women's Health | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 13 | $ 13 | 13
Percentage Change In Sales By Segment Of Business | 1.70% | (1.60%) |
United States | Wound Care and Other | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 475 | $ 495 | 480
Percentage Change In Sales By Segment Of Business | (4.00%) | 3.10% |
United States | Remicade | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,417 | $ 2,019 | 2,508
Percentage Change In Sales By Segment Of Business | (29.80%) | (19.50%) |
United States | Simponi/Simponi Aria | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,166 | $ 1,127 | 1,155
Percentage Change In Sales By Segment Of Business | 3.50% | (2.40%) |
United States | Stelara | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 6,388 | $ 5,938 | 5,240
Percentage Change In Sales By Segment Of Business | 7.60% | 13.30% |
United States | Tremfya | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,844 | $ 1,503 | 926
Percentage Change In Sales By Segment Of Business | 22.70% | 62.30% |
United States | Other Immunology | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 17 | $ 21 | 0
Percentage Change In Sales By Segment Of Business | (18.40%) |  |
United States | COVID-19 | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 120 | 634 | 0
Percentage Change In Sales By Segment Of Business | (81.10%) |  |
United States | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 36 | $ 41 | 44
Percentage Change In Sales By Segment Of Business | (10.80%) | (7.60%) |
United States | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,494 | $ 1,508 | 1,587
Percentage Change In Sales By Segment Of Business | (1.00%) | (4.90%) |
United States | Other Infectious Diseases | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 30 | $ 66 | 104
Percentage Change In Sales By Segment Of Business | (55.50%) | (36.00%) |
United States | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 151 | $ 172 | 183
Percentage Change In Sales By Segment Of Business | (12.50%) | (5.80%) |
United States | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,714 | $ 2,550 | 2,314
Percentage Change In Sales By Segment Of Business | 6.50% | 10.20% |
United States | RISPERDAL CONSTA | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 257 | $ 287 | 296
Percentage Change In Sales By Segment Of Business | (10.40%) | (2.90%) |
United States | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 447 | $ 338 | 298
Percentage Change In Sales By Segment Of Business | 32.40% | 13.30% |
United States | DARZALEX | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 4,210 | $ 3,169 | 2,232
Percentage Change In Sales By Segment Of Business | 32.80% | 42.00% |
United States | ERLEADA | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 968 | $ 813 | 583
Percentage Change In Sales By Segment Of Business | 19.20% | 39.30% |
United States | IMBRUVICA | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,390 | $ 1,747 | 1,821
Percentage Change In Sales By Segment Of Business | (20.40%) | (4.00%) |
United States | ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 74 | $ 119 | 373
Percentage Change In Sales By Segment Of Business | (37.80%) | (68.10%) |
United States | Other Oncology | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 289 | $ 110 | 83
Percentage Change In Sales By Segment Of Business |  | 31.70% |
United States | OPSUMIT | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,132 | $ 1,147 | 1,008
Percentage Change In Sales By Segment Of Business | (1.30%) | 13.70% |
United States | UPTRAVI | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,104 | $ 1,056 | 955
Percentage Change In Sales By Segment Of Business | 4.50% | 10.50% |
United States | Other | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 110 | $ 163 | 169
Percentage Change In Sales By Segment Of Business | (32.30%) | (3.70%) |
United States | Other | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 376 | $ 446 | 600
Percentage Change In Sales By Segment Of Business | (15.50%) | (25.70%) |
United States | XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,473 | $ 2,438 | 2,345
Percentage Change In Sales By Segment Of Business | 1.40% | 4.00% |
United States | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 193 | $ 308 | 564
Percentage Change In Sales By Segment Of Business | (37.40%) | (45.40%) |
United States | HIPS | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 943 | $ 878 | 793
Percentage Change In Sales By Segment Of Business | 7.30% | 10.70% |
United States | KNEES | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 851 | $ 787 | 743
Percentage Change In Sales By Segment Of Business | 8.20% | 5.90% |
United States | TRAUMA | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,882 | $ 1,819 | 1,648
Percentage Change In Sales By Segment Of Business | 3.50% | 10.40% |
United States | SPINE,SPORTS & OTHER | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,645 | $ 1,642 | 1,595
Percentage Change In Sales By Segment Of Business | 0.20% | 2.90% |
United States | ADVANCED | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,784 | $ 1,761 | 1,535
Percentage Change In Sales By Segment Of Business | 1.30% | 14.90% |
United States | GENERAL | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,113 | $ 2,105 | 1,714
Percentage Change In Sales By Segment Of Business | 0.40% | 22.70% |
United States | CONTACT LENSES/OTHER | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,522 | $ 1,398 | 1,213
Percentage Change In Sales By Segment Of Business | 8.90% | 15.20% |
United States | SURGICAL | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 468 | $ 459 | 344
Percentage Change In Sales By Segment Of Business | 2.00% | 33.50% |
Non-US |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 46,363 | $ 46,619 | 39,451
Percentage Change In Sales By Segment Of Business | (0.60%) | 18.20% |
Non-US | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 8,354 | $ 8,519 | 8,088
Percentage Change In Sales By Segment Of Business | (1.90%) | 5.30% |
Non-US | Pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 23,959 | $ 23,726 | 19,440
Percentage Change In Sales By Segment Of Business | 1.00% | 22.00% |
Non-US | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 5,899 | $ 5,907 | 4,880
Percentage Change In Sales By Segment Of Business | (0.10%) | 21.00% |
Non-US | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,769 | $ 3,576 | 1,808
Percentage Change In Sales By Segment Of Business | 5.40% | 97.80% |
Non-US | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,323 | $ 3,641 | 3,435
Percentage Change In Sales By Segment Of Business | (8.70%) | 6.00% |
Non-US | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 9,052 | $ 8,590 | 7,275
Percentage Change In Sales By Segment Of Business | 5.40% | 18.10% |
Non-US | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,071 | $ 1,085 | 1,015
Percentage Change In Sales By Segment Of Business | (1.30%) | 6.90% |
Non-US | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 845 | $ 927 | 1,025
Percentage Change In Sales By Segment Of Business | (8.90%) | (9.60%) |
Non-US | Medical Devices |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 14,050 | $ 14,374 | 11,923
Percentage Change In Sales By Segment Of Business | (2.30%) | 20.60% |
Non-US | Medical Devices | Interventional Solutions |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,131 | $ 2,135 | 1,594
Percentage Change In Sales By Segment Of Business | (0.20%) | 34.00% |
Non-US | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,267 | $ 3,462 | 2,984
Percentage Change In Sales By Segment Of Business | (5.60%) | 16.00% |
Non-US | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 5,793 | $ 5,945 | 4,983
Percentage Change In Sales By Segment Of Business | (2.60%) | 19.30% |
Non-US | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,859 | $ 2,831 | 2,362
Percentage Change In Sales By Segment Of Business | 1.00% | 19.80% |
Non-US | OTC | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,249 | $ 3,034 | 2,761
Percentage Change In Sales By Segment Of Business | 7.10% | 9.90% |
Non-US | Skin health/Beauty | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,015 | $ 2,141 | 2,100
Percentage Change In Sales By Segment Of Business | (5.90%) | 1.90% |
Non-US | Oral Care | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 871 | $ 1,008 | 958
Percentage Change In Sales By Segment Of Business | (13.60%) | 5.10% |
Non-US | Baby Care | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,104 | $ 1,188 | 1,141
Percentage Change In Sales By Segment Of Business | (7.10%) | 4.10% |
Non-US | Women's Health | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 891 | $ 905 | 888
Percentage Change In Sales By Segment Of Business | (1.50%) | 1.80% |
Non-US | Wound Care and Other | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 224 | $ 243 | 240
Percentage Change In Sales By Segment Of Business | (8.00%) | 1.70% |
Non-US | Remicade | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 722 | $ 935 | 893
Percentage Change In Sales By Segment Of Business | (22.80%) | 4.80% |
Non-US | Simponi/Simponi Aria | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,017 | $ 1,148 | 1,088
Percentage Change In Sales By Segment Of Business | (11.40%) | 5.50% |
Non-US | Stelara | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,335 | $ 3,196 | 2,467
Percentage Change In Sales By Segment Of Business | 4.40% | 29.60% |
Non-US | Tremfya | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 824 | $ 624 | 421
Percentage Change In Sales By Segment Of Business | 32.00% | 48.20% |
Non-US | Other Immunology | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 0 | $ 3 | 11
Percentage Change In Sales By Segment Of Business |  | (73.30%) |
Non-US | COVID-19 | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,059 | $ 1,751 | 0
Percentage Change In Sales By Segment Of Business | 17.60% |  |
Non-US | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 972 | $ 953 | 920
Percentage Change In Sales By Segment Of Business | 2.00% | 3.60% |
Non-US | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 449 | $ 575 | 597
Percentage Change In Sales By Segment Of Business | (21.90%) | (3.60%) |
Non-US | Other Infectious Diseases | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 289 | $ 297 | 292
Percentage Change In Sales By Segment Of Business | (2.60%) | 1.70% |
Non-US | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 493 | $ 495 | 439
Percentage Change In Sales By Segment Of Business | (0.40%) | 12.80% |
Non-US | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,426 | $ 1,472 | 1,339
Percentage Change In Sales By Segment Of Business | (3.10%) | 10.00% |
Non-US | RISPERDAL CONSTA | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 228 | $ 305 | 346
Percentage Change In Sales By Segment Of Business | (25.30%) | (11.80%) |
Non-US | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,176 | $ 1,368 | 1,312
Percentage Change In Sales By Segment Of Business | (14.10%) | 4.30% |
Non-US | DARZALEX | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,767 | $ 2,854 | 1,958
Percentage Change In Sales By Segment Of Business | 32.00% | 45.80% |
Non-US | ERLEADA | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 913 | $ 478 | 176
Non-US | IMBRUVICA | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,394 | $ 2,622 | 2,307
Percentage Change In Sales By Segment Of Business | (8.70%) | 13.60% |
Non-US | ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,696 | $ 2,178 | 2,097
Percentage Change In Sales By Segment Of Business | (22.10%) | 3.90% |
Non-US | Other Oncology | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 283 | $ 458 | 738
Percentage Change In Sales By Segment Of Business | (38.30%) | (37.90%) |
Non-US | OPSUMIT | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 651 | $ 672 | 631
Percentage Change In Sales By Segment Of Business | (3.20%) | 6.60% |
Non-US | UPTRAVI | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 218 | $ 181 | 138
Percentage Change In Sales By Segment Of Business | 20.40% | 31.10% |
Non-US | Other | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 202 | $ 232 | 247
Percentage Change In Sales By Segment Of Business | (12.80%) | (5.90%) |
Non-US | Other | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 590 | $ 673 | 794
Percentage Change In Sales By Segment Of Business | (12.30%) | (15.20%) |
Non-US | XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 0 | $ 0 | 0
Percentage Change In Sales By Segment Of Business | 0.00% | 0.00% |
Non-US | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 255 | $ 254 | 231
Percentage Change In Sales By Segment Of Business | 0.10% | 9.90% |
Non-US | HIPS | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 571 | $ 602 | 487
Percentage Change In Sales By Segment Of Business | (5.10%) | 23.60% |
Non-US | KNEES | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 508 | $ 538 | 427
Percentage Change In Sales By Segment Of Business | (5.70%) | 26.10% |
Non-US | TRAUMA | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 989 | $ 1,066 | 966
Percentage Change In Sales By Segment Of Business | (7.20%) | 10.40% |
Non-US | SPINE,SPORTS & OTHER | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,198 | $ 1,256 | 1,104
Percentage Change In Sales By Segment Of Business | (4.60%) | 13.80% |
Non-US | ADVANCED | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,785 | $ 2,861 | 2,304
Percentage Change In Sales By Segment Of Business | (2.60%) | 24.10% |
Non-US | GENERAL | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,008 | $ 3,085 | 2,679
Percentage Change In Sales By Segment Of Business | (2.50%) | 15.20% |
Non-US | CONTACT LENSES/OTHER | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,022 | $ 2,043 | 1,781
Percentage Change In Sales By Segment Of Business | (1.00%) | 14.70% |
Non-US | SURGICAL | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 837 | $ 788 | 581
Percentage Change In Sales By Segment Of Business | 6.20% | 35.70% |
UNITED STATES Exports | Remicade | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 204 | $ 236 | 346
Percentage Change In Sales By Segment Of Business | (13.60%) | (31.90%) |
CHINA | OTC | CONSUMER HEALTH and PHARMACEUTICAL |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers |  | $ 400 | $ 400

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ErleadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINESPORTSOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_CONSUMERHEALTHAndPHARMACEUTICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |